Effects of Coenzyme Q10 in PSP and CBD

This study has been completed.

Sponsor:

Information provided by:

Lahey Clinic

ClinicalTrials.gov Identifier:

NCT00532571

First received: September 18, 2007

Last updated: September 19, 2007

Last verified: September 2007

History of Changes

Tracking Information

First Received Date ^ICMJE

September 18, 2007

Last Updated Date

September 19, 2007

Start Date ^ICMJE

January 2004

Primary Completion Date

Not Provided

Current Primary Outcome Measures ^ICMJE

Not Provided

Original Primary Outcome Measures ^ICMJE

Not Provided

Change History

Complete list of historical versions of study NCT00532571 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures ^ICMJE

Not Provided

Original Secondary Outcome Measures ^ICMJE

Not Provided

Current Other Outcome Measures ^ICMJE

Not Provided

Original Other Outcome Measures ^ICMJE

Not Provided

Descriptive Information

Brief Title ^ICMJE

Effects of Coenzyme Q10 in PSP and CBD

Official Title ^ICMJE

Effects of Coenzyme Q10 in PSP and CBD, A Randomized, Placebo-Controlled, Double Blind Cross Over Pilot Study

Brief Summary

To compare the efficacy, safety and tolerability of Coenzyme Q 10 versus placebo in patients with atypical parkinsonian syndromes corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP) ).

Detailed Description

Not Provided

Study Type ^ICMJE

Interventional

Study Phase

Phase 2
Phase 3

Study Design ^ICMJE

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double-Blind
Primary Purpose: Treatment

Condition ^ICMJE

Progressive Supranuclear Palsy
Neurological Disorders

Intervention ^ICMJE

Drug: CoQ10

Study Arm (s)

Not Provided

Publications *

Not Provided

* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.

Recruitment Information

Recruitment Status ^ICMJE

Completed

Enrollment ^ICMJE

Not Provided

Completion Date

September 2005

Primary Completion Date

Not Provided

Eligibility Criteria ^ICMJE

Inclusion Criteria:

Patients fulfilling the diagnostic criteria of PSP and CBD (above) and who were diagnosed within the past 5 years
Age > 40
Subjects receiving anticholinergics, amantadine, dopamine agonists, carbidopa/levodopa, eldepryl, or comtan must be on a stable dose for at least 30 days prior to baseline visit.
Patients agreeable to participate in the study.

Exclusion Criteria:

Prior or concurrent therapy with anticholinergics, amantadine,a dopamine agonist,carbidopa/levodopa or comtan within 30 days of the baseline visit.
Parkinsons disease or any other atypical parkinsonism; Parkinsonism due to drugs.
History of pallidotomy, thalamotomy, deep brain stimulation or fetal tissue transplant.
Previous use of coenzyme Q10 within 60 days of the baseline visit.

Gender

Both

Ages

40 Years and older

Accepts Healthy Volunteers

Contacts ^ICMJE

Contact information is only displayed when the study is recruiting subjects

Location Countries ^ICMJE

United States

Administrative Information

NCT Number ^ICMJE

NCT00532571

Other Study ID Numbers ^ICMJE

CoQ10 with PSP/CBD

Has Data Monitoring Committee

Responsible Party

Not Provided

Study Sponsor ^ICMJE

Lahey Clinic

Collaborators ^ICMJE

Not Provided

Investigators ^ICMJE

Principal Investigator:

Diana Apetauerova, MD

Lahey Clinic

Information Provided By

Lahey Clinic

Verification Date

September 2007

^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP

To Top